Metastatic Renal Cell Cancer-Systemic Therapy.

Abstract

Management of metastatic renal cell carcinoma (mRCC) has evolved considerably in the past 10 years due to better understanding of tumor biology. This development has changed mRCC to a chronic progressive disease with several lines of treatment options. The introduction of several new targeted therapies including immunotherapy has improved median overall survival of approximately 1 year to >2 years in mRCC.

• Authors: Amit Joshi, Arvind Sahu, Vanita Noronha, Vijay Patil, Kumar Prabhash
• Journal: Indian journal of surgical oncology (Indian J Surg Oncol) Vol. 9 Issue 1 Pg. 97-104 (Mar 2018) ISSN: 0975-7651 [Print] India
• PMID: 29563746 (Publication Type: Journal Article)